Canopy Growth Corporation Common Shares (CGC)
CGC trades on Nasdaq in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/1737927/000119312526270260/0001193125-26-270260-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-03-31. Converted from CAD at 1.4258 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | CGC on Nasdaq |
| Sector | Health Care |
| Industry | Medicinal Chemicals and Botanical Products |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001737927 |
| SEC industry code | Medicinal Chemicals & Botanical Products |
| Incorporated in | Canada |
| Canadian listing | TSX: WEED |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $199.6M |
| Net income | -$184.4M |
| Operating income | -$113.4M |
| Net margin | -92.4% |
| Operating margin | -56.8% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $255.8M |
| Total assets | $784.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.2× |
Reported in CAD; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-06 |
| Cash and burn | $255.8M cash; operating cash flow -$11.2M a quarter. | Report 2026-03-31 |
| Shares outstanding | 423,352,668 (2026-11-04); 342,195,956 a year earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2023-12-20 | Source 2023-12-20 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-02-06 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-10-16 |
| Auditor | PKF O'Connor Davies, LLP, New York, New York, United States; changed auditors 1 time in 24 months | 8-K 4.01 2026-08-07 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $388K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2026 2026-03-31 | $199.6M | -$184.4M | -$44.8M | $255.8M | $163.7M | $199.6M | 10-K 2026-06-15 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-02-13 |
| Latest annual report | 10-K | 2026-06-15 |
| Latest quarterly / interim | 10-Q | 2026-11-06 |
| Latest current report | 8-K | 2026-11-06 |
| Latest proxy | DEFA14A | 2026-10-16 |
Source: SEC EDGAR submissions feed, 765 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -14.0% |
| 1 month | -26.5% |
| 3 months | -44.5% |
| Year to date | -50.8% |
| 1 year | -49.0% |
| From 52-week high | -70.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medicinal Chemicals and Botanical Products
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| USNA | USANA Health Sciences Inc. | $13.54 | +2.27% | $250.3M |
| MDWD | MediWound Ltd. | $13.55 | +5.04% | $195.0M |
| ACB | Aurora Cannabis Inc. Common Shares | $4.61 | -6.68% | $303.1M |
| SNDL | SNDL Inc. Common Shares | $1.34 | -2.19% | $326.0M |
| NAGE | Niagen Bioscience Inc. | $2.01 | -2.66% | $159.2M |
| TLRY | Tilray Brands Inc. Common Stock | $2.34 | -3.70% | $345.8M |
| GLAS | Glass House Brands Inc. Subordinate Voting Shares | $1.29 | +1.57% | $113.5M |
| OBIO | Orchestra BioMed Holdings Inc. | $7.12 | -1.79% | $560.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier